Dr. Markus brings over 20 years of experience in biopharmaceuticals and clinical development to his role as chief medical officer at Arcus. Dr. Markus established a unique track record of late-stage development experience during a 13-year tenure at Amgen in increasing roles of responsibility, including as vice president of global development. Dr. Markus oversaw the development and approval of multiple products and was also the first R&D head for the biosimilars division, leading the development of a 10-product pipeline across multiple therapeutic areas, including oncology and rheumatology. He also oversaw the development that led to the approval of CAYSTON® for cystic fibrosis at Corus Pharma prior to its acquisition by Gilead. Most recently, Dr. Markus founded Dantari, a clinical-stage oncology-focused antibody-drug conjugate company, where he served as president, CEO and member of the Board. Dr. Markus received his M.D. and a Ph.D. in epidemiology from the University of Southern California.